Previous 10 | Next 10 |
Clene (CLNN): FY GAAP EPS of -$1.10 misses by $0.65.Revenue of $0.21M beats by $0.01M.Press Release For further details see: Clene EPS misses by $0.65, beats on revenue
Interim Phase 2 data indicate that CNM-Au8 has a homeostatic effect on brain bioenergetics Topline data from a Phase 2 ALS trial and two Phase 2 target engagement studies in MS and Parkinson’s disease expected in 2H 2021 Full enrollment in Phase 3 registrational t...
Clene (CLNN) and its wholly owned subsidiary Clene Nanomedicine announce that over 50% of participants have been enrolled in the HEALEY ALS Platform Trial being conducted at sites of the Northeast ALS ((NEALS)) consortium.The trial is a multi-center one evaluating the safety and efficacy...
SALT LAKE CITY, March 09, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to revolutionizing the treatment of neurodegen...
SALT LAKE CITY, March 03, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) today announced that its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to revolutionizing the treatm...
Interim data from a Phase 2 target engagement study show that CNM-Au8 treatment was associated with improvements across key CNS bioenergetic metabolites in Parkinson’s disease patients Initiation of a Phase 2 proof-of-concept trial in Parkinson’s disease pati...
Blinded interim data from VISIONARY-MS continue to support the potential of CNM-Au8 to drive meaningful neurological functional improvements in MS patients Interim REPAIR-MS results provide further evidence of CNM-Au8’s homeostatic effect on brain bioenergetics in...
SALT LAKE CITY, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, today announced that it will present updated interim dat...
Study to evaluate CNM-ZnAg in acutely symptomatic, non-hospitalized COVID-19 patients SALT LAKE CITY, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) today announced that its wholly owned subsidiary Clene Nanom...
Gainers: ATA Creativity Global (AACG) +204%.Anavex Life Sciences (AVXL) +81%.Lizhi (LIZI) +76%.CPS Technologies (CPSH) +48%.Annovis Bio (ANVS) +43%.Sify Technologies (SIFY) +42%.Tian Ruixiang (TIRX) +40%.Cyclerion Therapeutics (CYCN) +39%.Cyclo Therapeutics (CYTH) +33%.Ato...
News, Short Squeeze, Breakout and More Instantly...
Clene plans to submit a briefing book to the U.S. Food and Drug Administration by July 13 as Part of Overall Process to Support Approval for CNM-Au8(R) for Treatment of ALS Type C interaction is aimed at obtaining FDA feedback on the potential pathway for a new drug application for CNM-Au8 as a...
Latest figures from the World Health Organization show that more than 8.5 million individuals around the globe are living with Parkinson’s disease . This disease is the fastest-growing neurodegenerative disorder globally, with the number of individuals with this illness more than doubli...
A look at the top 10 most actives in the United States Kazia Therapeutics Limited (KZIA) rose 106.5% to $1.38 on volume of 71,739,314 shares Renalytix plc (RNLX) rose 41.4% to $0.4269 on volume of 54,892,134 shares Maxeon Solar Technologies Ltd. (MAXN) fell 7.4% to $0.1951 on volume of 45...